Clinical Trial Details
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults with Brain Tumors Official Title:
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults with Brain Tumors
Start Date September 11, 2013
End Date June 30, 2014
| Gender Preference |
|None|| Age Group |
|0 - 29 years|
| Principal Investigator |
|Chenue Abongwa, MD|
| Contact Info |
Chenue Abongwa, 319-356-4328
Participants in this research study have been diagnosed with a brain tumor that has cells with special proteins called somatostatin receptors.
The purpose of this research study is to see if participants' tumors can be identified using a special procedure called a positron emission tomography (PET) scan. They will have an injection with a radioactive drug called 68Gallium-DOTA-tyr3-Octreotide (68Ga-DOTATOC) that binds to tumor cells that have somatostatin receptors and then have a PET scan. Participants will then have a "low dose" computed tomography (CT) scan immediately after the PET scan on the same scanner. 68Ga-DOTATOC is considered investigational, which means that it has not yet been approved by the U.S. Food and Drug Administration (FDA). The FDA has granted permission to conduct this study under an investigator's new drug (IND) application.
About 30 people will take part in this study conducted by investigators at the University of Iowa.
|201302711 ; abongwa ; brain tumor ; cancer ; imaging ; pediatric ; |